Adjuvant Endocrine Therapy for Premenopausal Women: ASCO Tumor Boards

Product ID : AETTB16
Price: $15.00
You will receive a link to your product from within 1 hour of purchase confirmation. Shipping charges do not apply to digital products.
E-mail to a friend



Breast cancer remains the leading cause of cancer related mortality in premenopausal women. Endocrine therapy is a critical part of adjuvant therapy in women with hormone receptor–positive breast cancer and has been shown to reduce the risk of recurrence and death from breast cancer. This is a case-based activity that includes discussion of a 40-year-old woman who is positive for a grade 2 infiltrating ductal carcinoma in the right breast, with immunohistochemistry studies revealing a strong ER (90%) and PR (80%) expression and negative for HER2 over expression. The patient has a family history of breast cancer in her mother, who was diagnosed in the last year at the age of 70. The patient elected to undergo a bilateral mastectomy with right sentinel lymph node biopsy with immediate latissimus and implant reconstruction, and following her surgery she was referred to a medical oncologist to discuss adjuvant therapy options. 

At the end of this course, users should be able to:

  • Discuss the incidence and characteristics of premenopausal breast cancer patients
  • Discuss the role of ovarian suppression and aromatase inhibitors as an adjuvant therapy
  • Understand the optimal therapy and duration of adjuvant hormonal therapy in premenopausal women

Faculty for this course include:

  • Prakash Peddi, MD, MS
  • Helen Krontiras, MD

IMPORTANT NOTE: This course expires on July 20, 2019. Participants must complete all necessary course components by this date.

Purchase the 2016 ASCO Tumor Boards Bundle to access to all 2016 ASCO Tumor Boards for added savings. Purchased separately, these items would be $180 altogether. When bundled, you save $55.